Alnylam Pharmaceuticals ($ALNY) EVP & CLO Reports Mandatory Sell-to-Cover Transaction
ALNYLAM PHARMACEUTICALS, INC.
Subscribe to track ALNY
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
📋 Form 4 Filed: ALNYLAM PHARMACEUTICALS, INC. ($ALNY) Insider: SUPRAN BRYAN (EVP, CLO and Secretary) Transaction: Disposed 1,758 shares of Common Stock @ $226.88 ($398,855.04 total value) Nature: Mandatory Sell-to-Cover for Tax Withholding Post-Transaction Holdings: 12,807 shares (Direct) Significance: Low (Non-discretionary tax sale)
Comprehensive Analysis
Transaction Overview
On October 2, 2026, Bryan Supran, Executive Vice President, Chief Legal Officer, and Secretary of Alnylam Pharmaceuticals, Inc. ($ALNY), sold 1,758 shares of common stock at an average price of $226.88 per share, representing an aggregate transaction value of approximately $398,855.04.
Nature of Transaction & Significance
This sale carries Low informational significance for market participants because it was non-discretionary. As noted in Footnote 1 of the filing, the shares were automatically sold by the company pursuant to a mandatory sell-to-cover provision in the award agreement to satisfy minimum statutory tax withholding obligations associated with the vesting and settlement of restricted stock units (RSUs).
Post-Transaction Holdings
Following the transaction, Mr. Supran retains direct ownership of 12,807 shares of Alnylam Pharmaceuticals common stock.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.